Trends in Relative Ratio Between Feline Calcium Oxalate and Struvite Uroliths Submitted From Three European Regions
World Small Animal Veterinary Association World Congress Proceedings, 2007
L. Davies1; J.P. Lulich2
1Hill's Pet Nutrition Nordic; 2University of Minnesota

World-wide the relative frequency of calcium oxalate increased from 2.5% in 1981 to 60% in 1994, stabilized ~60% between 1994 and 2002, and declined to ~50% since 2002. The causes for these changes are unknown. However, changes in nutritional practices are an important consideration.

We investigated whether a similar development occurred in three European regions. All uroliths were analysed by Minnesota Urolith Center.

In Denmark and Benelux, a similar increase in relative frequency of calcium oxalate urolithiasis occurred with a delay of about five years, and it has stabilized at ~65% since 1997/1998. In Spain, the relative frequency of calcium oxalate has remained stable at ~45% from 2001, i.e., struvite uroliths have consistently been the most frequently submitted stone type.

We hypothesize that the decrease in relative frequency of struvite uroliths in Denmark and Benelux is associated, at least in part, with dietary struvite prophylaxis and dissolution. Whether the recent global trend towards decline of calcium oxalate will be reproduced here remains to be seen. Maintained ratio could be a consequence of less widespread management to reduce risk factors of calcium oxalate or to differences in the cat populations. The continuous preponderance of struvite uroliths in Spain might have resulted from less emphasis on struvite prevention and dissolution.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Lotte Davies
Hill's Pet Nutrition
Denmark


MAIN : Abstracts - Oral : Calcium Oxalate & Struvite Uroliths
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27